Design, synthesis, molecular docking and biological evaluation of novel pyrazole derivatives bearing quinoxalinone moiety as multi-targeted anticancer agents
作者:Cynthia E Theodore、A.M. Anusuya、G. Sivaiah、Ranjana Jain、C.S. Ananda Kumar、S.B. Benaka Prasad、M.S. Raghu、Fahad A. Alharti、M.K. Prashanth、Byong-Hun Jeon
DOI:10.1016/j.molstruc.2023.135765
日期:2023.9
quinoxalinone-based pyrazole derivatives (4a-h) were designed and synthesized. The potency of newly synthesized molecules to inhibit the antiproliferation of the human cancer cell lines MCF-7 (breast), HCT-116 (colon), and A549 (lung) was examined. The most effective compounds against the examined cancer cell lines were 4e, 4f, 4 g, and 4 h. Among these, compounds 4e and 4 h had a strong anticancer activity that
基于多靶点靶向药物设计技术,设计并合成了一系列新的基于喹喔啉酮的吡唑衍生物(4a-h )。检测了新合成分子抑制人类癌细胞系 MCF-7(乳腺癌)、HCT-116(结肠癌)和 A549(肺癌)抗增殖的效力。对检查的癌细胞系最有效的化合物是4e、4f、4 g 和 4 h。其中,化合物4e和4h具有与索拉非尼相当的强抗癌活性。还测试了有效化合物(4e、4f、4g 和 4h)抑制胸苷酸合成酶 (TS)、BRaf 和 EGFR 激酶体外活性的能力。含 IC 50TS 酶、BRaf 激酶和 EGFR 激酶的值分别为 1.16 至 2.97 μM、1.28 至 3.69 μM 和 1.93 至 4.28 μM,所有研究的化合物均显示出明显的抑制作用。在合成的杂交体中,化合物 4 h 对 MCF-7、HCT-116 和 A549 细胞系的 IC 50值分别为 2.04、2.69 和 1.93 μM,对 TS、BRaf